Plx-4032
Code | Size | Price |
---|
TAR-T8654-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8654-10mg | 10mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8654-50mg | 50mg | £128.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8654-100mg | 100mg | £151.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8654-200mg | 200mg | £215.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T8654-500mg | 500mg | £316.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
PLX-4032 is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
CAS:
1029872-54-5
Formula:
C23H18ClF2N3O3S
Molecular Weight:
489.92
Pathway:
MAPK
Purity:
0.9994
SMILES:
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F
Target:
Raf
References
Chapman, Paul, B, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation.[J]. New England Journal of Medicine, 2011.
Smalley K S M . PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.[J]. Current Opinion in Investigational Drugs, 2010, 11(6):699-706.